International Lung Cancer Congress | Conference

Moving Toward Newfound Diagnostic, Treatment Paradigms in Lung Cancer

July 23rd 2020

Ignacio I. Wistuba, MD, discusses the clinical importance of histological subtyping of lung cancer and additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer.

New Tools Support Translational Strides in NSCLC

July 23rd 2020

In non–small cell lung cancer, single cell analytics, genome editing, and next-generation animal models represent just some of the modern modalities advancing translational research.

Adjuvant Osimertinib Possesses Potential to Revolutionize NSCLC Treatment, But Longer Follow-Up Needed

July 23rd 2020

The disease-free survival benefit observed with the third-generation EGFR TKI osimertinib as an adjuvant treatment in patients with EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial is striking.

Dr. Aggarwal on Emerging Treatment Approaches in ALK+ NSCLC

July 23rd 2020

Charu Aggarwal, MD, MPH, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer.

Dr. Gandara on the Utility of TMB in NSCLC

July 23rd 2020

David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.

Dr. Bazhenova on New Developments in RET-Rearranged NSCLC

July 28th 2019

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses new developments in RET-rearranged non–small cell lung cancer.

Dr. Wakelee on Advances in EGFR-Mutant NSCLC Treatment

July 28th 2019

Heather A. Wakelee, MD, professor of medicine (oncology), Stanford University Medical Center, discusses osimertinib and its role in treating patients with EGFR-mutant non–small cell lung cancer.

Immunotherapy Combos, Novel Strategies Aim to Address Unmet Needs in Small Cell Lung Cancer

July 27th 2019

With the arrival of immunotherapy to the small cell lung cancer armamentarium, combination approaches with targeted therapies are now in the pipeline to stimulate further clinical activity, such as adding PARP or CHK1 inhibitors.

Wealth of Immunotherapy Combinations Places Emphasis on Biomarkers for NSCLC

July 27th 2019

The magnitude of data becoming available on immunotherapy combinations for patients with non–small cell lung cancer has made treatment selection complicated.

Novel Therapies Elicit Excitement in KRAS+ NSCLC

July 27th 2019

The early potential shown with the KRAS inhibitor AMG 510 coupled with several promising ongoing combination studies has ushered in the beginning of an exciting era for the treatment of KRAS-mutant non–small cell lung cancer.

Dr. Peters on Creating Algorithms for Personalized Therapy in NSCLC

July 27th 2019

Solange Peters, MD, PhD, of University Hospital Center Vaudois and Lausanne University in Switzerland, discusses the rapid advances in the lung cancer field and the importance of using biomarkers to create personalized immunotherapy treatments for patients.

Dr. Borghaei on CheckMate-227 Trial Updates in NSCLC

July 27th 2019

Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology, professor of the Department of Hematology/Oncology, and co-director of the Immune Monitoring Facility at Fox Chase Cancer Center, discusses recent announcements from the CheckMate-227 trial in non–small cell lung cancer.

Osimertinib Frontline Standard of Care for EGFR+ NSCLC

July 27th 2019

The frontline standard of care for patients with EGFR-mutant non–small cell lung cancer remains an EGFR TKI, most commonly osimertinib in the United States.

Immunotherapy Continues to Evolve Multimodal Stage III NSCLC Treatment

July 27th 2019

Checkpoint inhibitors in the neoadjuvant setting, as consolidation post-chemoradiation, or in combination with concurrent chemoradiation, are all strategies actively being pursued in the locally advanced non–small cell lung cancer setting.

"Hitting the Target" Should Be Focus of Next-Generation Agents in Lung Cancer

July 26th 2019

The future generation of agents in lung cancer should be evaluated in improved predictive biomarker-driven trials to identify patients who are most likely to benefit or have detriment for both TKIs and checkpoint inhibitors.

Dr. Herbst on Immuno-Oncology Combinations in Lung Cancer

July 26th 2019

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses combinations with immunotherapy in lung cancer.

Dr. Reckamp on Pivotal Data in METex14-Altered NSCLC

July 26th 2019

Karen L. Reckamp, MD, MS, discusses pivotal findings with the highly selective MET inhibitors, tepotinib and capmatinib in patients with MET exon 14-altered advanced non–small cell lung cancer.

Future Lung Cancer Research Requires Precision Medicine Ecosystem

July 26th 2019

There is a growing need to share information across research settings and the community, with the rapid introduction of new biomarkers, cancer detection strategies, immunotherapies, and targeted therapies. This synchronization of system biology tool datasets could help create a new digital ecosystem focused on precision medicine.

Window-of-Opportunity Strategies Continue to Make Headway in Lung Cancer

July 26th 2019

Paul A. Bunn Jr, MD, highlights the benefits of preoperative window-of-opportunity studies, specifically with immunotherapy in lung cancer.

Novel Research Methods Could Expedite New Drug Development

July 26th 2019

Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic.